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Abstract
Background: α/β-Hydrolase domain 6 (ABHD6) is one of the major enzymes for endocannabinoid 2-arachidonoylglycerol
(2-AG) hydrolysis in microglia cells. Our recent studies have shown that a selective ABHD6 inhibitor WWL70 has anti-
inflammatory and neuroprotective effects in animal models of traumatic brain injury and multiple sclerosis. However, the
role of ABHD6 in the neuroinflammatory response and the mechanisms by which WWL70 suppresses inflammation has
not yet been elucidated in reactive microglia.
Methods: The hydrolytic activity and the levels of 2-AG in BV2 cells were measured by radioactivity assay and liquid
chromatography coupled with tandem mass spectrometry (LC-MS/MS). The expression of cyclooxygenase-2 (COX-2) and
prostaglandin E2 (PGE2) synthases in microglia treated with lipopolysaccharide (LPS) with/without WWL70 was determined
by western blot and quantitative RT-PCR. The conversion of 2-AG to PGE2 or PGE2-glyceryl ester (PGE2-G) was assessed by
enzyme-linked immunoassay (EIA) or LC-MS/MS. The involvement of ABHD6 in PGE2 production was assessed using
pharmacological inhibitors and small interfering RNA (siRNA). The effect of WWL70 on PGE2 biosynthesis activity in
the microsome fraction from BV2 cells and experimental autoimmune encephalopathy (EAE) mouse brain was also
examined.
Results:We found that WWL70 suppressed PGE2 production in LPS-activated microglia via cannabinoid receptor-
independent mechanisms, although intracellular levels of 2-AG were elevated by WWL70 treatment. This reduction was
not attributable to WWL70 inhibition of ABHD6, given the fact that downregulation of ABHD6 by siRNA or use of KT182, an
alternative ABHD6 inhibitor failed to suppress PGE2 production. WWL70 attenuated the expression of COX-2 and PGES-1/2
leading to the downregulation of the biosynthetic pathways of PGE2 and PGE2-G. Moreover, PGE2 production from
arachidonic acid was reduced in the microsome fraction, indicating that WWL70 also targets PGE2 biosynthetic enzymes,
which are likely to contribute to the therapeutic mechanisms of WWL70 in the EAE mouse model.
Conclusions: WWL70 is an anti-inflammatory therapeutic agent capable of inhibiting PGE2 and PGE2-G production,
primarily due to its reduction of COX-2 and microsomal PGES-1/2 expression and their PGE2 biosynthesis activity in
microglia cells, as well as in the EAE mouse brain.
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Background
2-Arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine,
also known as anandamide (AEA), are the two principal
endogenous ligands for cannabinoid type 1 (CB1) receptor
expressed primarily in neurons [1] and the CB2 receptor
mostly expressed in microglia and astrocytes, although
they are also found in neuronal cells in the brain stem and
other regions in the central nervous system (CNS) [2, 3].
A growing body of evidence has indicated that modulation
of the endocannabinoid system plays an essential role in
ameliorating the development of several neurological dis-
eases such as multiple sclerosis [4, 5], traumatic brain in-
jury [6], and neuropathic pain [7]. Activation of CB1 and/
or CB2 receptors contributes to the suppression of inflam-
mation and reduction of glutamate excitotoxicity [8, 9].
In addition to functioning as a full agonist for CB1 and
CB2 receptors, 2-AG is also a precursor for arachidonic
acid (AA) and its derivative prostaglandins (PGs; PGD2,
PGE2, PGF2α, PGI2, and TXA2) in the brain [10, 11].
Although PGs are lipid mediators involved in cell homeo-
stasis, they also mediate the inflammatory response in a
variety of pathological conditions [12]. There is a consen-
sus that AA is mainly provided from diet or derived from
glycerophospholipids catalyzed by phospholipase A2 [13].
AA is further metabolized to PGs by cyclooxygenases
(COXs) and PG synthases. However, recent studies have
shown that inhibition or deletion of the primary 2-AG
hydrolytic enzyme monoacylglycerol lipase (MAGL) sig-
nificantly reduces the brain levels of AA and PGs, suggest-
ing that 2-AG plays an essential role in the production of
PGs especially in the CNS [14].
The majority of the endocannabinoid-hydrolyzing en-
zymes belong to the serine hydrolase superfamily [15].
Using a novel technology that detects active serine hydro-
lases [16], WWL70 was revealed to be a specific inhibitor
for α/β-hydrolase domain 6 (ABHD6), a 2-AG hydrolytic
enzyme in the brain [17]. The inhibitory property of
WWL70 on ABHD6 was further demonstrated by several
later studies [18–20]. Although the results from our la-
boratory and others have shown that only ~4% of 2-AG
hydrolysis in the mouse brain and spinal cord is attribut-
able to ABHD6 under physiological conditions [21],
ABHD6 contributes significantly to the 2-AG hydrolysis
in microglia/macrophages, in which there is no or little
expression of MAGL [18, 19]. Recently, we have found
that WWL70 exerts therapeutic effects in mouse models
of traumatic brain injury [22] and experimental
autoimmune encephalomyelitis (EAE) [23] through at-
tenuating microglial activation, COX-2 expression, and
the impaired function of the blood-brain barrier. In
addition, WWL123, a derivative of WWL70 with high per-
meability to the blood-brain barrier, was also protective in
a mouse model of epilepsy [24]. However, the exact
mechanism by which inhibition of ABHD6 results in
the reduction of inflammatory response remains
elusive.
In this study, we found that treatment with WWL70
substantially reduced PG production in BV2 and primary
microglia cells. Surprisingly, this reduction was not due
to inhibition of ABHD6 by WWL70 but was attributable
to its interference with the metabolic pathway from AA
to PGE2. Moreover, we found that WWL70 inhibited
microsomal PGE2 synthesis activity, which is the primary
cause for PGE2 reduction. Thus, we report here a novel




BV2 microglial cells [25] were cultured in complete
DMEM containing 5% heat-inactivated fetal bovine
serum (Life Technologies, Grand Island, NY) under hu-
midified 5% CO2 environment. The cells were main-
tained by medium change every other day. One day
prior to experiment, cells were plated on 24-well plates
to reach 90% confluence at the beginning of experiment.
For primary microglia culture, Sprague–Dawley rats were
purchased from Charles River Laboratories (Frederick,
MD) and housed in the animal facility of the Uniformed
Services University of the Health Sciences (USUHS).
All animal protocols were approved by the USUHS
Institutional Animal Care and Use Committee. P2
Sprague–Dawley rat pups (male and female) were sacri-
ficed and their brains removed. Mixed glial cultures
were then prepared from the cortices after careful re-
moval of the meninges and brain stem. The cortices
were then triturated by serial trituration with a 10-ml
pipette, 18-G needle (3×), 22-G needle (3×), and finally,
a 25-G needle (2×) in culture medium (DMEM con-
taining 10% fetal bovine serum, 1% glutamax, and 1%
antibiotic-antimycotic). After trituration, the suspen-
sion was filtered using a 70-micron mesh and then pel-
leted at 168×g for 10 min at room temperature. Cells
were resuspended in culture medium, seeded into T75
flasks, and incubated in a CO2 incubator. The medium
was replaced every 2–3 days. After 14 or 15 days in cul-
ture, primary microglia were harvested by differential
shaking on an orbital shaker for 1 h at 200 rpm in a
CO2 incubator. The medium, containing the detached
microglia, was collected and centrifuged at 671×g for
5 min at room temperature. Cells were then resuspended
with DMEM containing 10% normal horse serum, 1% glu-
tamax, and 1% streptomycin/penicillin and transferred to
uncoated plates at a density of 2.5 × 105 cells/mL.
Reagents
KT182, an ABHD6 inhibitor, and HT-01, the activity-
based protein profiling (ABPP) probe specific for
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ABHD6, were kindly provided by Drs. Hsu and Cravatt
[26]. 2-Arachidonoylglycerol [glycerol-1,2,3-3H] was
from American Radiolabeled Chemicals Inc. (Saint
Louis, MO). Cyclooxygenase inhibitor assay kits includ-
ing COX inhibitor and recombinant COX-1 or COX-2
activity assay kit were from Cayman Chemical (Ann
Arbor, MI). siRNA (FlexiTube Mm_abhd6_3 and
Allstars Negative Control) and HiPerfect transfection
reagent were from QIAGEN (Valencia, CA). WWL70,
methyl arachidonyl fluorophosphonate (MAFP), SR141716
(SR1), SR144528 (SR2), 2-AG, 2-AG-d8, and AA were pur-
chased from Cayman Chemical. Other reagents including
lipopolysaccharide (LPS) were purchased from Sigma-
Aldrich (St. Louis, MO).
PGE2 enzyme immunoassay
A multi-well cell culture plate was prepared 1 or 2 days
prior to the test. The cell culture medium was replaced
with pre-warmed medium containing the ABHD6 inhibi-
tor WWL70 (10 μM) and incubated for 15 min. The cells
were treated with 10 μM of 2-AG for 15 min, followed by
addition of 100 ng/ml LPS for BV2, or 2 ng/ml LPS for
primary microglia. After incubation for 18 h, the culture
medium was collected. Before addition to the enzyme-
linked immunoassay (EIA), the medium was centrifuged
at 5000 rpm for 2 min with a table top centrifuge to ex-
clude residual cells. To determine the role of WWL70 on
PGE2 production in vivo, EAE was induced by subcutane-
ous injection of myelin oligodendrocyte glycoprotein pep-
tide 35–55 (MOG35–55) in 8-week-old female C57BL/6
mice, and the clinical score was assessed as we reported
recently [23]. WWL70 (10 mg/kg, i.p.) was given starting
at the disease onset and then once a day until the end of
the test. The mouse forebrain at 3 weeks post-
immunization was dissected and kept frozen at −80 °C
until use. The forebrain tissue was homogenized with
one-fifth volume of 0.02% trifluoroacetic acid (TFA) and
one volume of acetonitrile using a Potter homogenizer at
4 °C. Homogenate was dispersed completely in 2 ml of
acetonitrile by vortex and stored at 4 °C overnight. Debris
was excluded by centrifugation at ×2000g for 5 min, and
then the supernatant was evaporated under the nitrogen
gas streaming in a water bath (approximately 35 °C). After
reconstitution with the EIA buffer, the levels of PGE2 were
measured following the manufacturer’s protocol (Cayman
Chemical, Ann Arbor, MI).
2-AG hydrolysis activity assay
Hydrolysis activity of 2-AG was assessed as previously
described [27]. For hydrolysis activity in intact cells, BV2
cells in a 24-well plate were pre-incubated with or with-
out inhibitor for 30 min at 37 °C, followed by washing
with pre-warmed DMEM plus 0.15% fatty acid-free BSA.
The cells were incubated with 0.2 ml of 10 μM
radiolabeled 3[H]-2-AG (33 nCi) in DMEM containing
0.15% fatty acid-free BSA. After 2 min of incubation, the
reaction was terminated by mixing with 0.4 ml chilled
methanol. The cell extract was transferred to a silanized
glass tube, followed by mixing with 0.4 ml of chloroform
by brief vortexing. The mixture was centrifuged at
×3000g for 5 min to separate the aqueous and organic
phases. Aliquot of the aqueous phase was mixed with
scintillation cocktail and measured in a scintillation
counter LS6500 (Beckman Coulter, Brea, CA). For hy-
drolysis activity in membrane fraction, BV2 cell hom-
ogenate was centrifuged at ×1400g for 5 min to remove
the debris, then ultracentrifuged at ×100,000g at 4 °C for
30 min. The pellet was resuspended with PBS, and pro-
tein concentration was determined by DC protein assay
kits using BSA as a standard (Bio-Rad). Four hundred
microliters of the membrane fraction (20 μg) was pre-
incubated in a silanized glass tube with or without
10 μM of WWL70 for 5 min at 37 °C, then mixed with
100 μl of 10 μM 3[H]-2-AG (33 nCi) in PBS containing
0.15% fatty acid-free BSA. After 2 min of incubation, the
reaction mixture was mixed with chilled 2 ml methanol/
chloroform (1:1). Radioactivity in the aqueous phase was
measured as described above.
Activity-based protein profiling and western blotting
One milligram per milliliter of the membrane fraction
prepared as above was pre-incubated with WWL70 at in-
dicated concentrations for 10 min at room temperature,
then mixed with 1 μM HT-01, a serine hydrolase probe
that specifically recognizes active ABHD6 enzymes [26], at
37 °C for 40 min. The reaction mixture was added to the
SDS-PAGE sample buffer and heated at 95 °C for 5 min.
Approximately 10 μg of the protein was loaded on SDS-
PAGE. The gel was scanned with a fluorescence imager,
Fuji FLA-5100 (Fujifilm, Edison, NJ) with an excitation
wavelength at 473 nm using FITC mode. The intensity of
the fluorescent band is proportional to the amount of ac-
tive ABHD6. Subsequently, the gel was transferred onto
PVDF membrane for western blotting with anti-calnexin
as a loading control for the membrane fraction.
For western blotting, cell lysate or microsome fraction
was prepared with RIPA buffer containing 150 mM
NaCl, 50 mM Tris-HCl (pH 8.0), 1% Triton X-100, 0.5%
Na deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA,
1 mM Na3VO4, 1 mM β-glycerophosphate, and protease
inhibitor cocktail (Roche Applied Sciences) for 5 min on
ice, followed by centrifugation at ×12,000g for 5 min at
4 °C to remove the debris. Transferred PVDF membrane
was pre-incubated with 5% BSA in PBS + 0.05% Tween-
20 (PBST) for 30 min, then incubated with antibodies
against β-actin (AC-74, Sigma-Aldrich) at 1:1000, cal-
nexin (T-40, Santa Cruz) at 1:1000, microsomal prosta-
glandin E2 synthase (mPGES)-1 (#160140, Cayman
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Chemical) at 1:500, mPGES-2 (#160145, Cayman
Chemical) at 1:500, and COX-2 (#160106, Cayman
Chemical) at 1:250 in PBST at 4 °C overnight. The trans-
ferred membrane was reacted with a secondary antibody
conjugated with horseradish peroxidase (Bio-Rad) at
1:2500 for 2 h, followed by visualization with ECL re-
agent (Thermo Scientific) using the LAS3000 imager
(Fujifilm). The relative intensity of COX-2 to β-actin was
quantified using ImageJ software (National Institutes of
Health), and the fold change compared to the LPS treat-
ment alone was presented.
LC-MS/MS analysis for 2-AG
Sample preparation for 2-AG quantification was carried
out based on a method published previously [28]. BV2
cells (90% confluence) in 10-cm dishes were treated with
WWL70 (10 μM) or MAFP (10 μM) for 1 h. After rins-
ing with PBS once, the cells were collected by centrifu-
gation at ×5000g for 2 min. The pellet was suspended
with 0.1 ml of 0.02% TFA and 1 nmole of 2-AG-d8 by
pipetting and dispersed in 4 ml of acetonitrile in a sila-
nized glass tube to precipitate the debris overnight at
−20 °C. The supernatant after centrifuged at ×5000g for
5 min was transferred to a new glass tube and evapo-
rated under a nitrogen gas stream in a mild hot water
bath (approximately 35 °C). 2-AG was resuspended with
0.1 ml of acetonitrile and stored at −80 °C until mass
analysis.
An HPLC system (1200 Series, Agilent Technologies,
Santa Clara, CA) was used with a reverse phase guard
column (Wide Pore C18 (ODS), 4 × 2 mm ID; Phenom-
enex, Torrance, CA), and the column (Sephasil Peptide
C18, 5 u, ST, 100 × 4.6 mm ID; Pharmacia Biotech
(Amersham), Piscataway, NJ) was maintained at 40 °C.
The mobile phase was composed of solvent A: 0.2% for-
mic acid in water, and solvent B: 0.2% formic acid in
methanol; the following gradient was used: 62% A/38%
B isocratic for 30 s, ramp to 90% B in 60 s, isocratic at
90% B for 18.5 min, ramp back to 62% A/38% B in 60 s,
and re-equilibrate at 62% A/38% B for 8 min. The flow
rate was 0.4 ml/min. The HPLC output was directed
into the TurboV electrospray ionization (ESI) source of
a Q-Trap 4000 mass spectrometer (AB Sciex, Framing-
ham, MA). The injection volume was 20 μl. LC-MS/MS
analysis was performed in a positive mode with the ion
source temperature of 600 °C, a spray voltage of 5.5 kV,
and a declustering potential of 45 V. Multiple reaction
monitoring (MRM) was performed on the transitions
m/z 379.5→287.5 for 2-AG and 386.5→293.5 for 2-AG-
d8. Calibration curves of the ratio of analyte (2-AG) to
internal standard (2-AG-d8) peak areas vs. concentration
ratio (at least seven different 2-AG concentrations at a
single fixed 2-AG-d8 concentration) were generated by
linear least squares fitting and used to calculate the 2-AG
concentrations in the samples (converting the observed
y-value (peak area ratio) of the samples into x-values (con-
centration ratios with a fixed internal standard
concentration).
LC-MS/MS for PGE2 and PGE2-G
The method for LCMS analysis of PGE2 and PGE2-gly-
cerol in positive ion mode was derived from a different
previously published procedure [29]. BV2 cells pre-
treated with or without 0.1 μg/ml of LPS for 8 h were
rinsed once with pre-warmed serum-free medium (Opti-
MEM, Thermo Fisher Scientific), then incubated with
Opti-MEM containing 10 μM 2-AG, 10 μM WWL70, or
both for 30 min in CO2 incubator. The medium was col-
lected and centrifuged at ×1000g for 5 min to remove
floating cells and stored at −80 °C until use. One milli-
liter of medium was mixed with 1.4 ng PGE2-d4 and
0.5 ng PGE2-G-d5 (Cayman Chemical) and acidified by
glacial acetic acid to 1% at final concentration. It was
loaded to a solid-phase extraction column (Oasis HLB
1 cc, Waters Corporation, Milford, MA) equilibrated
with 0.5% acetic acid and methanol. After washing with
0.5% acetic acid followed by 0.5% acetic acid with 15%
methanol, PGs were eluted with 1.5 ml of methanol.
After evaporation in nitrogen streaming under approxi-
mately 30 °C, the PGs were reconstituted with aceto-
nitrile/water (1:2).
The same LCMS system described above was used with
a Higgins Analytical TARGA C18 3 μm 2.1 × 100 mm col-
umn (Nest Group Inc., Southborough, MA). The HPLC
gradient was as follows: the column was equilibrated at
80% 5 mM ammonium formate in water (buffer A)/20%
4:1 acetonitrile/water with 5 mM ammonium formate
(buffer B); after sample injection, the gradient for elution
of analytes went from 20 to 80% buffer B in 15 min. The
column was re-equilibrated by ramping to 100% buffer B
in 1 min, holding at 100% buffer B for 2 min to flush,
ramping back down to the initial HPLC buffer compos-
ition (80%/20% A:B) in 2 min, and holding at the initial
buffer composition for 8 min before the next injection.
The flow rate was 0.2 mL/min, the column temperature
was 40 °C, and the injection volume was 25 μL. The ion
source temperature was 550 °C, and the declustering po-
tential was 40 V. Since the HPLC buffer contained ammo-
nium ions, the precursor ions for PGE2 and PGE2-glycerol
were ammonium adducts (M + 18). The following MRM
transitions were used: for PGE2, precursor ion mass
370.3 Da to fragment ion mass 335.2 Da (collision energy
(CE) 12.5 V) and 317.1 Da (CE 15 V); for d4-PGE2, 374.3
to 339.2 Da (CE 12.5 V) and 321.3 Da (CE 15 V); for
PGE2-glycerol, 444.4 to 409.2 Da (CE 12.5 V) and
299.2 Da (CE 26 V); and for d5-PGE2-glycerol, 449.4 to
414.1 Da (CE 12.5 V) and 299.2 Da (CE 26 V).
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qRT-PCR
Total RNA from BV2 cells or primary microglia treated
with reagents for 8 h was isolated using TRIzol (Life
Technologies) according to the manufacturer’s protocol.
Five hundred nanograms of RNA were used for cDNA
synthesis using MAXIMA First Strand cDNA synthesis
kit with dsDNAse (Thermo Fisher Scientific) following
the manufacturer’s protocol. The Cq value of negative
control without reverse transcription was >40 due to the
treatment with DNase. Complementary DNA from 10 ng
RNA was employed for qPCR in the presence of 250 nM of
gene-specific primers (mPGES-1 forward, 5′-TGTCCAA
ATCCTGTCTTCCA-3′, reverse, 5′-GGTTCTGGAGCAC
ACCCTAT-3′; mPGES-2 forward, 5′-GAAATGGCTG-
CAGAATTGAA-3′, reverse, 5′-AAGGAGAATGGTGCT
CCAAG-3′; COX-2 forward, 5′-GAAATGGCTGCAGAA
TTGAA-3′, reverse, 5′-AAGGAGAATGGTGCTCCAAG-
3′; ABHD6 forward, 5′-CATTCCAATCCTGGCATTTG
TTG-3′, reverse, 5′-ATGGTGTGCGTAGCGAACTT-3′;
and GAPDH forward, 5′-AGGTCGGTGTGAACGGATT
TG-3′, reverse, 5′-TGTAGACCATGTAGTTGAGGTCA-
3′) using Power SYBR Green PCR master mix (Life Tech-
nologies) in 12 μl reaction mixture. Thermal cycling
condition was 95 °C for 10 min, followed by 40 cycles of
95 °C × 15 s and 60 °C × 60 s performed by LightCycler 480
II (Roche Life Science, Indianapolis, IN). Gene-specific PCR
amplification was confirmed by the melting curve profile
using LightCycler 480 system program showing 80 to 85 °C
of single melting temperature for all the genes tested.
GAPDH was used as a reference gene because its Cq
value was constant among the cells tested (Cq value
is 15.7 ± 0.1, mean ± SD). The PCR amplification lin-
earity was confirmed using serial diluted cDNA show-
ing the consistent amplification in the concentration
range tested (r2 > 0.998).
siRNA transfection
BV2 cells in a 24-well plate (50 to 70% confluent) were
transfected with siRNA for the mouse ABHD6 gene
(Mm_abhd6_3, QIAGEN) or the negative control using
HiPerfect transfection reagent according to the manufac-
turer’s protocol. Briefly, 37.5 ng siRNA was mixed with
100 μl DMEM without FBS, then added 6 μl of the
transfection reagent and incubated for 10 min at room
temperature. The siRNA complex suspension was added
to the cells drop-wise. Total RNA was isolated from the
cells after 1 day of incubation and qRT-PCR was per-
formed to examine the expression of ABHD6 and
GAPDH. Otherwise, the transfected cells after 2 days of
incubation were used to prepare membrane fraction for
ABPP to assess ABHD6 hydrolytic activity, followed by
western blot with the calnexin antibody as a loading
control.
Enzyme activity assay
The COX assay was carried out using the COX inhibitor
screening assay kit from Cayman Chemical. Briefly,
ovine recombinant COX-1 or human recombinant
COX-2 was pre-incubated in 0.1 M Tris-HCl (pH 8.0)
and EDTA (1 mM) buffer with WWL70 (10 μM), SC-
560 (0.33 μM), or Dup-697 (0.3 μM) for 5 min at 27 °C.
Then, 10 μM of AA was added and incubated for 1 min
at 27 °C. The reaction was stopped by adding 1 N HCl.
Stannous acid was then added to convert PGH2 to the
stable product PGF2α. The resultant mixture was applied
to a prostaglandin EIA to measure the total amount of
prostaglandins including PGE2 and PGF2α. The PGE2
biosynthesis assay was performed using microsomes de-
rived from BV2 cells treated with LPS for 8 h or brain
tissue from EAE mouse at day 21 post-immunization [23].
BV2 cells were suspended with 0.1 M potassium phosphate
(pH 7.4), 0.25 M sucrose, 1 mM β-glycerophosphate, 1 mM
sodium vanadate, 1 μMMAFP, and protease inhibitor cock-
tail (Roche) and disrupted by sonication for 15 s, while the
brain tissue was homogenized with a Potter homogenizer
with the potassium phosphate buffer at 4 °C. These homog-
enates were centrifuged at ×1400g for 10 min at 4 °C to
remove the debris, followed by further centrifugation at
×10,000g for 10 min at 4 °C. The supernatant was ultracen-
trifuged at ×170,000g for 1 h at 4 °C to precipitate the
microsome fraction. The pellet was suspended with potas-
sium phosphate buffer containing glutathione (2.5 mM) by
brief sonication. One hundred micrograms per milliliter of
BV2 microsomes was pre-incubated with WWL70, MK886
(3 μM), SC-560 (1 μM), or NS398 (10 μM) for 5 min at
23 °C, then mixed with 10 μM of AA for 1 min at 23 °C.
500μg/ml brain microsomes were incubated with
10 μM of AA for 2 min at 23 °C. The reaction was
stopped by mixing with stannous acid (5 mg/ml in 0.1 N
HCl) to deactivate the enzyme and convert intermediate
PGH2 to PGF2α, followed by the measurement of PGE2
concentration by EIA as described above. The activity was
determined after subtraction with the amount of PGE2 in
the microsome fraction incubated without substrate.
Statistics
All data are expressed as mean ± SD. The GraphPad
Prism 7 (GraphPad Software Inc., San Diego, CA) was
used for statistical analysis. The statistical comparison
among the drug-treated groups (different drugs or the
same drug at various concentrations) was performed
using one-way ANOVA followed by Turkey’s test; while
in experiments with both LPS, LPS + 2-AG, or LPS + AA
groups, two-way ANOVA was performed. An unpaired t
test was used for data comparison between two groups.
Statistical significance was set at P < 0.05, with single,
double, and triple asterisks to denote p < 0.05, 0.01, and
0.001, respectively.
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Results
WWL70 inhibited 2-AG hydrolysis and elevated 2-AG level
in BV2 cells via inhibition of ABHD6
2-AG hydrolysis to AA in BV2 cell membrane was con-
firmed by deuterated AA generation using LC-MS/MS
(Additional file 1: Figure S1). Because AA can be rapidly
metabolized, we measured the simultaneously produced
glycerol derived from 2-AG using radioactive assay. In the
presence of WWL70, 2-AG hydrolysis in BV2 cells was




Fig. 1 Inhibition of ABHD6 by WWL70 increased the 2-AG levels in BV2
cells. a BV2 cells were treated with WWL70 or MAFP for 30 min and then
incubated with 3[H]-2-AG at 37 °C for 2 min. Cell lysates were mixed with
MeOH/CHCl3 to separate the organic from aqueous phase. The amount
of 3[H]-glycerol, the product of 2-AG hydrolysis, was measured in the
aqueous phase. Inhibitors were added at either 1 or 10 μM. Data are
represented as mean± SD (n= 3). Triple asterisks denote p< 0.001
compared to the drug-treated groups. b The membrane fraction from
BV2 cells was incubated with WWL70 for 10 min, reacted with HT-01
probe (1 μM) at 37 °C for 40 min, and then applied to SDS-PAGE. The gel
was scanned to detect active ABHD6, followed by western blotting with
an anti-calnexin antibody. c BV2 cells were incubated with 10 μM of WWL70
or MAFP for 1 h before harvest. Cell lipids were extracted with acetonitrile
plus 0.02% TFA together with 2-AG-d8 as an internal standard. 2-AG was
identified and quantified with LC-MS/MS based on the ratio to the internal
standard. Data are represented as mean±SD (n=6). Double and triple
asterisks denote p<0.01 and 0.001, respectively, compared to control
a
b
Fig. 2 WWL70 blocked PGE2 production independently on CB
receptor signaling. a BV2 cells were incubated with WWL70 for
15 min, before addition of 2-AG (10 μM) for 15 min, and subsequent
addition of LPS (100 ng/ml). After 18 h, the culture medium was
tested for PGE2 by EIA. b BV2 cells were treated with LPS, WWL70
with/without CB1R antagonist SR1 (SR141716A), or CB2R antagonist
SR2 (SR144528) for 18 h before the culture medium was assayed for
PGE2 content. There were no significant differences in the amount
of PGE2 with or without antagonist. Representative experiment,
mean ± SD (n = 3), out of three similar independent experiments.
Single and triple asterisks denote p < 0.05 and 0.001, respectively,
compared to the drug-treated groups
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inhibitor, methyl arachidonyl fluorophosphonate (MAFP)
[30], almost completely inhibited the hydrolytic activity
(Fig. 1a). This result is consistent with a previous report
[19] indicating that ABHD6 is one of the main 2-AG
hydrolytic enzymes in BV2 cells. ABPP is a recently
developed technology to detect serine hydrolases using a
probe that specifically binds to the active enzymes but not
the inactive or the inhibitor bound forms [15]. Using the
HT-01 probe, we found that WWL70 at 1 μM and 10 μM
dramatically reduced the band intensity of ABHD6
(Fig. 1b). Next, we examined whether inhibition of
ABHD6 could alter the intracellular levels of 2-AG with
LC-MS/MS. At 1 h after WWL70 (10 μM) treatment,
2-AG was increased by 20% compared to untreated cells
(Fig. 1c). Treatment with MAFP (10 μM) also significantly




Fig. 3 WWL70 suppressed COX-2 expression. Western blots of BV2 cell
lysates with different treatment protocols, showing COX-2 expression with
β-actin controls. The blots shown here are representative of three
independent experiments. a BV2 cells were incubated with synthetic CB
receptor agonist, WIN55,212-2, or 2-AG for 15 min, before addition of LPS
(0.1 μg/ml) for 18 h. Single and double asterisks denote p<0.05 and 0.01,
respectively, compared to the LPS treatment alone (mean± SD, n=3).
b BV2 cells were treated with AA or endocannabinoids at the indicated
concentrations for 15 min followed by incubation with LPS for 18 h. Single,
double, and triple asterisks denote p<0.05, 0.01, and 0.001, respectively,
when compared to the LPS treatment alone (mean± SD, n=3). c BV2 cells
were treated with WWL70 for 15 min, followed by the addition of 2-AG for
a further 15 min, before addition of LPS for 18 h. Relative COX-2 expression
levels to β-actin were shown under each blot after normalizing with the
LPS-treated conditions. Single asterisk denotes p< 0.05 (mean± SD, n=3).




Fig. 4 WWL70 suppressed microsomal PGESs and COX-2 mRNA
expression. qRT-PCR of mPGES-1 (a), mPGES-2 (b), or COX-2 (c)
mRNA isolated from BV2 cells treated with WWL70 (10 μM) for
15 min, before addition of 2-AG (10 μM) for 15 min, and then LPS
(0.1 μg/ml) for 18 h. Data are represented as relative expression to
control condition after normalization with GAPDH (mean ± SD,
n = 4). Single and double asterisks denote p < 0.05 and
0.01, respectively
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WWL70 reduced PGE2 production in LPS-activated BV2
cells
It has been reported that the hydrolysis of 2-AG by
MAGL is one of the major sources of AA and its deriva-
tive PGs in the mouse brain [10, 14]. Because ABHD6,
but not MAGL is the primary 2-AG hydrolytic enzyme
in BV2 cells [18, 19], we tested the possibility that
WWL70 could reduce PGE2 production in BV2 cells.
Treatment with LPS (100 ng/ml) for 18 h increased
PGE2 production, and this increase was completely
blocked by WWL70 at either 1 or 10 μM (Fig. 2a). To
further determine if PGE2 production is affected by
2-AG metabolism, cells were incubated for 18 h in the
presence of 2-AG and LPS. Exogenous addition of 2-AG
together with LPS caused a sevenfold increase of PGE2
production compared to cells incubated with LPS alone,
suggesting that the increased PGE2 was derived from
2-AG. In the presence of 2-AG, the production of
PGE2 was reduced substantially by 1 and 10 μM
WWL70 (Fig. 2a).
To determine whether PGE2 reduction by WWL70 is
mediated by cannabinoid receptors, cells were co-
incubated with the CB1 receptor antagonist SR141716A
(SR1) or the CB2 receptor antagonist SR144528 (SR2).
Neither CB1 nor CB2 antagonist reversed the PGE2 re-
duction by WWL70, suggesting that cannabinoid recep-
tor signaling was not involved in the inhibitory effect of
WWL70 (Fig. 2b).
The expression levels of COX-2 and mPGES in LPS-activated
BV2 cells were reduced by WWL70
Since COX-2 is involved in the metabolism of AA to
PGE2, the potentiation of 2-AG on PGE2 production in
LPS-activated BV2 cells might be due to the increased ex-
pression of COX-2. To test this possibility, BV2 cells were
treated with LPS for 18 h in the presence of different con-
centrations of 2-AG. Expression of COX-2 was induced
by LPS and further potentiated by 2-AG (Fig. 3a). How-
ever, the CB1 and CB2 cannabinoid receptor agonist
WIN55,212-2 dramatically suppressed the expression of
COX-2. This result suggests that the expression of COX-2
is differentially regulated by 2-AG and the other synthetic
cannabinoid receptor agonists. To determine the action of
other endocannabinoid (eCB) ligands, AEA, which acti-
vates either CB receptors with comparable efficiency to 2-
AG and is hydrolyzed to AA by fatty acid amide hydrolase,
a b
c
Fig. 5 The highly selective ABHD6 inhibitor KT182 did not reduce PGE2 production. a Activity-based protein profiling with the ABHD6-specific probe
HT-01 shows reduced ABHD6 activity in the membrane fraction of BV2 cells in the presence of KT182. b Using membrane fraction from BV2 cells,
treatment with KT182, WWL70, or MAFP for 5 min showed decreased hydrolysis of 2-AG by quantifying released radioactive glycerol as described in
Fig. 1. Relative 2-AG hydrolysis as compared to the non-treated group are shown (mean ± SD; n = 3). c BV2 cells were incubated with DMEM plus
WWL70 (10 μM) or KT182 (100 nM) for 15 min, before addition of 10 μM 2-AG or AA for 15 min, followed by addition of LPS (100 ng/ml) for 18 h.
Culture medium was assayed for PGE2 by EIA (mean ± SD, n = 3). Single, double, and triple asterisks denote p < 0.05, 0.01, and 0.001, respectively
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was also tested in LPS-treated BV2 cells and shown to up-
regulate the expression of COX-2. Addition of AA also
potentiated the expression of COX-2, whereas the Noladin
ether, which is an unhydrolyzable eCB ligand, did not
show any increase (Fig. 3b). These results suggest that
COX-2 upregulation by eCBs was dependent on the pro-
duction of AA from their hydrolysis. In line with this no-
tion, treatment with WWL70 reduced the increase of
COX-2 by 2-AG (Fig. 3c), suggesting that the reduced
COX-2 expression was likely due to the limited produc-
tion of AA. Consistently, the enhanced mRNA expression
of mPGES-1 and mPGES-2 (Fig. 4a, b) by LPS was also
potentiated by 2-AG and reduced by WWL70 similar to
that of COX-2 (Fig. 4c).
PGE2 reduction by WWL70 was independent of ABHD6
inhibition
To further examine whether pharmacological inhibition
of ABHD6 leads to the reduced PGE2 levels, a recently
developed ABHD6 inhibitor KT182 was tested. KT182 is
a derivative of piperidyl-1,2,3-triazole urea inhibitors
with high potency and selectivity to target ABHD6 [26].
Activity-based protein profiling using KT182-treated
BV2 membrane fraction showed a strong reduction in
active ABHD6 at 1 and 10 nM of KT182 (Fig. 5a), which
is consistent with a previously published report that the
IC50 of this inhibitor is less than 5 nM [26]. The inhib-
ition of 2-AG hydrolysis activity by KT182 in the BV2
membrane fraction was similar to that of WWL70
(Fig. 5b). However, unlike WWL70 which reduced the
production of PGE2 in LPS-activated BV2 cells, PGE2
production was not affected by KT182 in the presence
or absence of either 2-AG or AA (Fig. 5c). These data
suggest that the inhibition of PGE2 production by
WWL70 might be independent of ABHD6 inhibition.
Next, we tested whether ABHD6 knockdown could
affect PGE2 production. 24 h after siRNA transfection,
the mRNA levels of ABHD6 were reduced by approxi-
mately 80% compared to the control siRNA-transfected
cells (Fig. 6a). The activity of ABHD6 in BV2 cells after
2 days siRNA transfection was also dramatically reduced
(Fig. 6b). Different from the results with WWL70, but
consistent with those with KT182, knockdown of
ABHD6 did not decrease PGE2 production in BV2 cells
treated with LPS in the absence or presence of 2-AG.
On the other hand, the production of PGE2 was slightly
increased in siABHD6 cells possibly due to the differ-
ences in cell population after transfection. The reduction
of PGE2 by WWL70 was similar in both control and
ABHD6 siRNA-transfected cells (Fig. 6c). These results
suggest that the inhibition of PGE2 production by
WWL70 is independent of its inhibition of ABHD6. Ra-
ther, the inhibitory action of WWL70 is likely due to its
interference with the biosynthetic pathway from AA to
PGE2, in which COXs and PGE2 synthases are involved.
WWL70 inhibited PGE2 synthesis
We examined whether WWL70 can modulate PGE2 pro-
duction by inhibition of the activity of PGE2 biosynthetic
enzymes, rather than through suppression of COX-2 and
PGES expression. Eighteen hours after treatment with LPS
to activate the PGE2 biosynthetic pathway, the medium was
replaced with fresh medium containing WWL70 with or
without either 2-AG or AA, and then incubated for a short
time period (30 min). The production of PGE2 was reduced
by WWL70 in the absence or the presence of 2-AG or AA
with a similar dose-response (Fig. 7a). KT182 treatment did
not alter the amount of PGE2 generated, except for the co-
treatment with 2-AG (Fig. 7b). Following the 30-min drug
treatment, the expression of mPGES-1 and mPGES-2 was
not changed (see western blot images in Fig. 7b). These re-
sults suggest that the enzymatic activity of COX-2 or PGES
is inhibited by WWL70, but not by KT182.
WWL70 inhibited PGE2-G production
We further examined the possibility that WWL70 in-
hibits PGE2-G production, since the biosynthetic path-
ways for synthesis of PGE2-G and PGE2 overlap. BV2 cells
a b
c
Fig. 6 ABHD6 siRNA knockdown did not reduce PGE2 production. a
qRT-PCR of ABHD6 transcript normalized to GAPDH, 24 h after
transfection with ABHD6-specific siRNA. b Membrane fraction prepared
from the transfected cells after 48 h transfection was reacted with the
ABHD6-specific HT-01 probe for 30 min to detect active ABHD6 enzyme,
followed by western blotting of calnexin as a loading control. c Cell
cultures after 48 h transfection were replaced with fresh medium with
LPS (0.1 μg/ml), WWL70 (10 μM), or 2-AG (10 μM). The culture medium
was collected after 18 h incubation and employed PGE2 EIA. Data are
analyzed with two-way ANOVA and represented as mean ± SD (n= 3).
Double or triple asterisks denote p< 0.01 or 0.001, respectively
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activated by LPS were subsequentially incubated with
non-serum containing medium with 2-AG or WWL70 for
30 min. The PGs in the medium were analyzed with LC-
MS/MS. Consistent with previous results, PGE2 produc-
tion was increased by LPS treatment and boosted in the
presence of 2-AG, whereas WWL70 decreased PGE2 pro-
duction (Fig. 8a). PGE2-G was detected only under the
conditions in the presence of 2-AG, but not in the absence
of 2-AG, indicating that the PGE2-G was derived from
2-AG (Fig. 8b). Treatment with WWL70 reduced the
PGE2-G significantly in the cells treated with LPS and
2-AG (Fig. 8b).
WWL70 targets PGE2 synthesis pathway in microsomes
To examine whether WWL70 directly inhibits the activ-
ity of COX enzymes, COX activity was assayed in vitro
in the presence of WWL70 using ovine COX-1 and hu-
man COX-2 recombinant proteins. WWL70 did not
have any effect on the activities of COX-1 or COX-2,
while their activities were completely blocked by the se-
lective COX-1 and COX-2 inhibitors SC560 and
Dup697, respectively (Additional file 2: Figure S2). Since
PGE2 biosynthetic enzymes are mainly localized in mi-
crosomes, we examined PGE2 production activity in
microsome fraction of BV2 cells activated by LPS for
a
b
Fig. 7 WWL70 inhibited PGE2 production in LPS-activated BV2 cells. Cells were treated with LPS (0.1 μg/ml) for 18 h to activate PGE2 biosynthesis
before replacement with fresh DMEM containing (a) 10 μM 2-AG or AA and WWL70 (1 or 10 μM) or (b) 10 μM 2-AG or AA and WWL70 (10 μM)
or KT182 (100 nM). The culture medium after 30 min incubation was employed PGE2 EIA. Using the microsome fraction, mPGES-1, mPGES-2, and
β-actin protein expression after 30 min incubation with different treatment conditions was examined by western blot as shown below the EIA
results. Data are represented as mean ± SD (n = 3). Single and triple asterisks denote p < 0.05 and 0.001, respectively
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8 h. Microsome fraction was incubated with 10 μM AA
for 1 min, followed by measurement of PGE2 (Fig. 9a).
The enzyme activity was reduced to 60% by WWL70,
whereas the mPGES-1 inhibitor MK886, the COX-1 in-
hibitor SC-560, and the COX-2 inhibitor NS398 COX-2
inhibitor reduced the enzymatic activity to 55, 39, and
36%, respectively. The dose-response study indicated
that the IC50 of WWL70 to inhibit the PGE2 biosyn-
thesis is about 100 nM (Fig. 9b), which is comparable to
its C50 for ABHD6 inhibition (70 nM) [17].
WWL70 suppressed the PGE2 production in primary
microglia cells
The effect of WWL70 on PGE2 production was also ex-
amined in rat primary microglia cells. Consistent with
the results obtained in BV2 cells, overnight WWL70
treatment abolished PGE2 production in LPS-activated
microglia, whereas KT182 did not have any inhibitory
effects (Fig. 10a). The addition of CB1 and CB2 receptor
antagonists did not reverse the inhibitory effect of
WWL70 on PGE2, suggesting that the effect of WWL70
was not mediated by cannabinoid receptor activation.
Primary microglia also replicated the effect in BV2 cells
of short-term drug treatment (30 min) on the reduction
of PGE2 production in LPS-stimulated cells supple-
mented with either 2-AG or AA (Fig. 10b). Cells were
treated with LPS for 18 h and then switched to the
medium containing WWL70 or KT182 for 30 min prior
to PGE2 EIA. PGE2 production was enhanced approxi-
mately tenfold in the presence of either 2-AG or AA,
a
b
Fig. 8 Determination of WWL70 inhibitory effect on PGE2 and PGE2-G
productions using LC/MS/MS. BV2 cells treated with LPS (0.1 μg/ml) for
8 h were replaced with fresh non-serum medium containing 2-AG with/
without WWL70 and incubated for 30 min. PGs in the medium was
extracted with SPE, then employed LC-MS/MS together with internal
standards PGE2-d4 and PGE2-G-d5 to determine the quantity of PGE2
(a) and PGE2-G (b). nd denotes not detected. Data are represented as
mean ± SD (n= 3 or 4)
a
b
Fig. 9 WWL70 inhibited microsomal PGE2 biosynthetic pathway.
Microsome from LPS-activated BV2 cells was pre-incubated with
WWL70 (3 μM), the mPGES-1 inhibitor MK886 (3 μM), the COX-1
inhibitor sc-560 (1 μM), or the COX-2 inhibitor NS398 (10 μM) for
5 min, then incubated with 10 μM AA for 1 min at 23 °C. The reaction
mixture after incubation was employed PGE2 EIA (a). Dose-dependent
inhibition of WWL70 was examined to determine its IC50 on PGE2
synthesis (b). Data are presented as mean ± SD (n = 3–6). Triple asterisks
denote p < 0.001, respectively
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indicating that the exogenous 2-AG and AA were me-
tabolized to PGE2. Again, WWL70 but not KT182 inhib-
ited PGE2 production.
WWL70 suppressed PGE2 production in EAE mouse brain
We have recently reported that WWL70 reduces micro-
glia activation, demyelination, and axonal injury and
ameliorates clinical symptoms in the EAE mouse model
[23]. To determine whether WWL70 could also inhibit
PGE2 production in vivo, we examined EAE mouse brain
tissue at day 21 post-immunization, at that time point,
the clinical scores are significantly reduced (Fig. 11a).
The levels of PGE2 in the EAE mice brain tissues in-
creased by 1.5-fold compared to the control mice
(Fig. 11b), which are similar to the previous study [31].
Treatment with WWL70 reversed the increased produc-
tion of PGE2 (Fig. 11b). Consistently, the PGE2 biosyn-
thetic activity in microsome fraction from the brain
tissue was also increased in the EAE-vehicle group and
reduced by WWL70 treatment (Fig. 11c). These results
suggest that the reduced PGE2 production may
contribute to the anti-inflammatory effect of WWL70 in
the EAE mouse model.
Discussion
WWL70, an ABHD6 selective inhibitor, possesses anti-
inflammatory and neuroprotective effects in LPS-
induced brain inflammation, traumatic brain injury, and
multiple sclerosis [18, 22, 23]. Although ABHD6 is
expressed in microglia and macrophages, and WWL70
can suppress microglia/macrophage activation, whether
ABHD6 is the primary target for the action of WWL70
remains elusive. In this study, we found that WWL70
treatment inhibited 2-AG hydrolysis and increased the
intracellular levels of 2-AG. WWL70 also significantly
reduced the production of PGE2 in LPS-activated BV2
and primary microglia cells. However, the increased
PGE2 production was not affected by another newly de-
veloped ABHD6 inhibitor KT182, and the inhibitory
effect of WWL70 was also observed in BV2 cells with
ABHD6 knockdown. These results suggest that the in-
hibitory effect of WWL70 on PGE2 production in LPS-
activated microglia is not dependent on its inhibition of
ABHD6 activity. Treatment with WWL70 reduced the
expression of both COX2 and mPGES, the metabolic
enzymes crucial for PGE2 production from AA. Further-
more, WWL70 directly inhibited the enzymatic activity
of microsomal PGE2 biosynthesis.
It has recently been demonstrated that the hydrolysis
of 2-AG by MAGL contributes significantly to the brain
levels of AA [14]. Inhibition or deletion of MAGL has
therapeutic effects in animal models of Parkinson’s dis-
ease [14] and Alzheimer’s disease [32] by blocking AA
and PG production, but not by cannabinoid-receptor-
mediated signaling. These recent findings highlight alter-
native therapeutic mechanisms of eCB-hydrolyzing
enzyme inhibitors. Although MAGL is the primary
enzyme for 2-AG hydrolysis in the brain, MAGL seems
to play a minor role in microglial cells and macrophages
because of its low expression [18, 19]. Instead, ABHD6
is one of the major hydrolyzing enzymes in macrophages
as ABHD6 inhibition caused a twofold increase in 2-AG
concentration [18]. We found that the increase in 2-AG
by WWL70 was relatively mild in BV2 cells (Fig. 1c),
possibly because the maximal inhibition by 10 μM of
WWL70 only accounts for 40% of the total 2-AG
hydrolysis (Fig. 1a). This result suggests that eCB signal
potentiation by increased 2-AG may not be a major
factor to the anti-inflammatory effect of WWL70 in
microglia.
It is of note that the exogenously added 2-AG in-
creased COX-2 protein expression in LPS-activated BV2
cells, whereas the commonly used synthetic CB receptor
agonist WIN55,212-2 had an opposite effect on COX-2
expression (Fig. 3a). The increase of COX-2 expression
a
b
Fig. 10 WWL70 inhibited PGE2 in primary microglia. PGE2 EIA of media
from primary microglia. a Cells were treated with LPS for 18 h in the
presence or absence of WWL70, KT182, or CB1 or CB2 receptor
antagonist. b Microglia were treated with LPS for 18 h before
media were replaced with DMEM containing WWL70 (10 μM),
KT182 (0.1 μM), AA (10 μM), or 2-AG (10 μM) and incubated for
30 min. The data are represented as mean ± SD (n = 3). Single
and triple asterisks denote p < 0.05 and 0.001, respectively
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by 2-AG is unlikely due to the activation of CB recep-
tors. Similarly, AEA that is also metabolized to AA, or
AA itself, increased the expression of COX-2 in LPS-
activated BV2 cells, whereas 2-arachidonyl glyceryl ether
(Noladin ether), an unhydrolyzable eCB ligand [33], had
no effect. These results indicate that addition of AEA
and 2-AG can increase AA production and facilitate
eicosanoid signaling in reactive microglia through the in-
creased expression of COX-2. Microsomal PGES1 and
PGES2 were also increased in LPS-activated microglia
and further potentiated by 2-AG. WWL70 suppressed
COX-2 and mPGES1/2 expression in the absence or
presence of 2-AG (Fig. 4). Taken together, these results
suggest that the suppression of the metabolic enzymes
to generate PGE2 contributes to the anti-inflammatory
effects of WWL70.
Recently, it has been reported that WWL70 in mouse
macrophages modulates the production of various PGs
including PG-glycerol esters (PG-Gs) [18], which are the
oxygenation product of 2-AG by COX-2 and PG
synthases [34]. These results suggest that WWL70 also
modulates the PGE2-G metabolism by increasing the
availability of 2-AG and alteration of COX-2 and
mPGES. Consistently, we also found that the generation
of PGE2, as well as PGE2-G, in LPS-activated microglia
was enhanced by the addition of 2-AG, and this increase
was significantly inhibited by WWL70 (Fig. 8). Several
studies have shown that PGE2-G triggers a pro-
inflammatory response [35–37], while PGD2-G has an
anti-inflammatory effect [18]. It is possible that WWL70
interferes with the PGE2-G synthetic pathway, which in
turn promotes the production of PGD2-G by the in-
creased availability of 2-AG (Fig. 12). It is still unclear
how various PG-Gs can modulate the pro- and anti-
inflammatory responses and how they differ from the ac-
tions of PGs, such as PGD2, PGE2, and PGF1α.
WWL123, a derivative of WWL70, has been shown to
be protective in the animal model of epileptic seizures
[24]. We have recently shown that the beneficial effect
of WWL70 in the mouse model of traumatic brain in-
jury [22] is at least in part due to its activation of CB1
and CB2 receptors, whereas in the experimental auto-
immune encephalomyelitis mouse model, the thera-




Fig. 11 WWL70 treatment attenuated PGE2 production in EAE mouse
brain. EAE mouse model was induced by immunization with the
MOG35–55 peptide. Intraperitoneal injection of WWL70 was started at
the disease onset and then once a day until the end of experiment.
The clinical scores at day 21 in EAE mice in vehicle and drug-treated
groups were shown (a). Mouse forebrain was dissected and used for
measuring PGE2 concentration (n = 10–11) (b). Microsome fraction
prepared from the brain tissue was applied to PGE2 synthetic activity
assay (n = 4–5) (c). Data are represented as mean ± SD. Single, double,
and triple asterisks denote p < 0.05, 0.01, and 0.001, respectively
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activation of CB2 receptors, as assessed by the use of the
selective CB2 receptor antagonist and the CB2 receptor
knockout mice [23]. Our present study suggests that the
beneficial effect of WWL70 in these animal models
might be also due to the reduced expression of COX-2
and PGES and the inhibition of the enzymatic activity
for PGE2 production. Indeed, we found that the IC50 of
WWL70 for PGE2 synthesis is about 100 nM, which is
comparable to its inhibition on ABHD6 (70 nM) re-
ported previously [17]. It has been demonstrated that
mPGES1 is localized in microglia in the EAE mouse
spinal cord and that PGE2 is a critical lipid mediator in
microglia causing neuroinflammation through activation
of EP2 receptor [38]. In LPS-activated BV2 microglia, we
observed that the expression of EP2 receptor was upreg-
ulated and reduced by WWL70 treatment (data not
shown). It is likely that the beneficial effect of WWL70
is also linked to the signaling mediated by EP2 receptor
or other PGE2 receptors.
Conclusions
Our data suggest that WWL70 can enhance the canna-
binoid signaling and reduction of the eicosanoid signal-
ing in microglia and may serve as an inhibitory
modulator for the metabolism from 2-AG to PGE2
(Fig. 12). Thus, we speculate that WWL70 might be
effective for the treatment of EAE and other neuroin-
flammatory and neurodegenerative diseases in which
activation of the COX-2-PGES-PGE2 axis is a major
contributor to the pathogenic mechanisms.
Additional files
Additional file 1: Figure S1. Conversion of 2-AG to AA in membrane
fraction. Membrane fraction from BV2 cells was incubated with
100 μM of 2-AG-d8 for 0, 1, or 5 min at 37 °C. AA-d8 extracted with
acetonitrile was applied to LC-MS/MS. Mass spectrograms for the
MRM transition from m/z 312 to m/z 93 is shown at three time
points. Transition peaks of each time point are shown in inset
represented as mean ± SD (n = 3). (PPTX 53 kb)
Additional file 2: Figure S2. Effect of WWL70 in recombinant COX
assay. Ovine recombinant COX-1 (A) or human recombinant COX-2 (B)
was pre-incubated in 0.1 M Tris-HCl (pH 8.0) and EDTA (1 mM) buffer with
WWL70 (10 μM), SC-560 (0.33 μM), or Dup-697 (0.3 μM) for 5 min at 27 °C.
Then, 10 μM of AA was added and incubated for 1 min at 27 °C. The reaction
mixture was applied for prostaglandins EIA to measure total amount of
prostaglandins. (PPTX 42 kb)
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